



LP-002: Advanced treatment for migraine

- Attractive out-license candidate
-

LCT seeks expressions of interest from pharmaceutical companies able to expand and accelerate the clinical development of LC-002 to market approval.

- ❖ LC-002 is a long-acting antagonist of the calcitonin gene-related peptide receptor
- ❖ Targets include:
 - Rapid treatment of migraine
 - Particularly when associated with defined causes e.g. menstruation
- ❖ *In vitro* – Extended plasma half-life
 - Albumin binding
 - Protection from protease degradation
- ❖ *In vivo* – In rodent models
 - Completing efficacy and pharmacokinetic profile
- ❖ Patented technology^{1,2}
- ❖ Parenteral delivery
- ❖ Once daily injection
- ❖ Safe

Migraine is a complex debilitating neurological disorder which is often characterised by recurrent severe headaches in one side of the head. It is generally preceded by sensory warning signs and other symptoms such as sensitivity to light and noise, nausea, vomiting, dizziness, etc.

The World Health Organization (WHO) compares severe migraine to dementia, quadriplegia and psychosis in terms of debilitation.

The global migraine drugs market was valued at \$1,713 million in 2017, and is expected to reach \$2,190 million by 2025, growing at a CAGR of 3.1% from 2018 to 2025.³

Growth of the market is driven by factors such as increasing incidences of migraine, rising female population, patent expiration, and stressed lifestyle. However side effects associated with migraine treatments are inhibiting market growth.

The search for treatments with greater tolerability has driven strong recent activity in the development and licensing of novel products to prevent or treat migraine.

1. M. A. Brimble, P. R. Dunbar, G. W. Williams and D. Verdon, "Amino Acid and Peptide Conjugates and Uses Thereof", *PCT International Patent* WO2016/103192, 2016, published 30 Jun 2016. [Application number PCT/IB2015/059901, filed 22 Dec 2015] *United States Patent Application* 15/535,956, 2018, published 4 Jan 2018.
2. P.W.R. Harris, K.M. Loomes, D.L. Hay, A. Jamaluddin, C.S. Walker, E.T. Williams, M.A. Brimble, "Peptide Conjugate CGRP Receptor Antagonists and Methods of Preparation and Uses Thereof" *PCT International Patent* WO2019087161, published 09 May 2019.
3. www.alliedmarketresearch.com

LCT is listed on the Australian (ASX: LCT) and US (OTCQX: LVCLY) stock exchanges. The company is incorporated in Australia, with its research and development and operations based in New Zealand.

lctglobal.com

FURTHER INFORMATION:

Dr Ken Taylor, CEO

T: +64 21 796 000

E: ktaylor@lctglobal.com

Dr Janice Lam, COO

T: +64 21 145 0779

E: jlam@lctglobal.com